Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening ...

Akero Therapeutics, Inc. announced that its management will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 1:40 p.m. P.T., with a live webcast available on their ...

Insider Trading Published 06/20/2025, 09:12 PM 0 Akero Therapeutics (AKRO) CFO White sells $89k in stock AKRO -1.28% ...

Akero Therapeutics has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is up 71.75% year-to-date. Overall AKRO ranks 4th on our list of the biotech stocks that are skyrocketing so far in 2025.

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands ...

Akero Therapeutics shares last traded at $43.15, with a volume of 76,195 shares trading hands. Specifically, Director G. Walmsley Graham bought 50,000 shares of Akero Therapeutics stock in a ...

Akero Therapeutics (NASDAQ: AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504.

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), sold 1,634 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and ...